Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunvozertinib in Untreated Advanced NSCLC With EGFR Uncommon Mutations
NCT07117890Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Feb 2025
- Primary completion
- Feb 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of sunvozertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Fudan University. Primary endpoint: Objective Response Rate at 24 months. Started Feb 2025; status: recruiting.
02
Drugs
sunvozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07117890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07117890.